Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
New Hampshire Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Karuna Therapeutics Inc
(NQ:
KRTX
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Mar 15, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Karuna Therapeutics Inc
< Previous
1
2
3
4
5
6
7
8
Next >
Why AAR Shares Are Trading Lower By 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
December 22, 2023
Shares of AAR Corp. (NYSE: AIR) fell during Friday’s session after the company reported mixed second-quarter financial results.
Via
Benzinga
S&P 500, Nasdaq 100 Aim For 8th Week Of Gains As Fed's Inflation Gauge Cools: What's Driving Markets Friday?
December 22, 2023
The S&P 500 and Nasdaq 100 indices are on the verge of achieving an impressive eight consecutive weeks of gains following a more significant decline than expected in the Federal Reserve’s favored...
Via
Benzinga
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Karuna Therapeutics Inc. (NASDAQ: KRTX) is a Leading Gainer in 12/22 Morning Trading
December 22, 2023
Via
Investor Brand Network
Where Karuna Therapeutics Stands With Analysts
December 12, 2023
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
December 22, 2023
Via
Benzinga
Stock Market Rally Is In Merry Mood Heading Into Christmas Weekend: Weekly Review
December 22, 2023
Despite a Wednesday tumble, the major indexes are right at 2023 highs.
Via
Investor's Business Daily
Gold Moves Higher; US Consumer Sentiment Improves In December
December 22, 2023
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining around 50 points on Friday. The Dow traded up 0.16% to 37,465.58 while the NASDAQ rose 0.28% to 15,005.25. The S&P 500...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
The Latest Analyst Ratings for Karuna Therapeutics
November 20, 2023
Via
Benzinga
Analyst Expectations for Karuna Therapeutics's Future
November 03, 2023
Via
Benzinga
With Karuna Therapeutics $14B Deal, Bristol Myers Is Serious For Re-Establishing Its Neurology Portfolio: Analyst
December 22, 2023
Earlier Friday, Bristol Myers Squibb & Co (NYSE: BMY) agreed to acquire Karuna Therapeutics Inc (NASDAQ: KRTX) for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 bill
Via
Benzinga
Karuna Therapeutics Jumps Following Takeover By Bristol Myers, Joins Rocket Lab USA, Altair Engineering And Other Big Stocks Moving Higher On Friday
December 22, 2023
U.S. stocks traded higher, with the Dow Jones index gaining around 50 points on Friday. Shares of Karuna Therapeutics, Inc. (NASDAQ: KRTX) rose sharply during Friday’s session following acquisition...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Health Care Company Bristol-Myers Squibb Announces Merger With Karuna Therapeutics
December 22, 2023
Via
Benzinga
Dow Rises 50 Points; Fed's Preferred Inflation Gauge Cools In November
December 22, 2023
U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 50 points on Friday. Following the market opening Friday, the Dow traded up 0.14% to 37,458.12 while the NASDAQ rose...
Via
Benzinga
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Bristol Myers Squibb Scoops Up Schizophrenia Player Karuna Therapeutics In Massive $14B Deal
December 22, 2023
On Friday, Bristol Myers Squibb & Co (NYSE: BMY) agreed to acquire Karuna Therapeutics Inc (NASDAQ: KRTX) for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion n
Via
Benzinga
Premarket Moves: Nike Dips 11%, Karuna Therapeutics Soars 48%
December 22, 2023
Friday has seen several stocks make notable moves ahead of the market opening, with Nike (NKE) and Karuna Therapeutics (KRTX) capturing the most attention.
Via
Talk Markets
Karuna Stock Soars On Bristol Myers' $14 Billion Takeover
December 22, 2023
Karuna is working on treatments for schizophrenia and Alzheimer's disease psychosis.
Via
Investor's Business Daily
KRTX STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Karuna Therapeutics, Inc. Is Fair to Shareholders
December 22, 2023
From
Halper Sadeh LLC
Via
Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
December 22, 2023
Via
Benzinga
Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
December 22, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
Karuna Therapeutics Announces The Lancet Publication of Data from Phase 3 EMERGENT-2 Trial Evaluating KarXT in Schizophrenia
December 14, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
PureTech Founded Entity Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia
November 29, 2023
From
PureTech Health plc
Via
Business Wire
Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia
November 29, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
Karuna Therapeutics Says Its Antipsychotic Candidate Shows Favorable Cardiovascular Safety Profile In Schizophrenia Patients
November 17, 2023
Karuna Therapeutics Inc (NASDAQ: KRTX) released results from its Phase 1b open-label, eight-week inpatient trial evaluating the effect of KarXT (xanomeline-trospium) on 24-hour ambulatory blood...
Via
Benzinga
Karuna Therapeutics Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in Schizophrenia
November 16, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
Karuna Therapeutics Reports Third Quarter 2023 Financial Results and Provides General Business Updates
November 02, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
Karuna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2023 Neuroscience Education Institute Congress
November 01, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
Karuna Therapeutics to Present at Upcoming Investor Conferences
November 01, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
Karuna Therapeutics to Announce Third Quarter 2023 Financial Results and Provide General Business Update on Thursday, November 2, 2023
October 19, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
Karuna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 36th European College of Neuropsychopharmacology (ECNP) Congress
October 04, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
Karuna Takes A Big Step In Schizophrenia Treatment. Shares Jump Higher.
September 28, 2023
Karuna Therapeutics says it could have the first new mechanism for schizophrenia treatment in decades.
Via
Investor's Business Daily
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.